CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue
Housing	$ 0	$ (6,519)	$ 141,953	$ (6,519)
Commercial rental	0	0	0	0
Tissue array products	129,032	153,228	341,596	390,458
Total revenue	129,032	146,709	483,549	383,939
Cost of Sales
Housing	0	58,625	123,091	58,625
Commercial rental	16,140	16,195	49,235	47,947
Tissue array products	77,895	104,848	222,329	294,172
Total cost of sales	94,035	179,668	394,655	400,744
Gross Profit	34,997	(32,959)	88,894	(16,805)
Operating Expenses:
Salaries and wages	51,279	45,581	153,839	127,157
Depreciation and amortization	37,264	37,516	112,272	110,509
Professional fees	28,529	14,268	66,264	71,376
Operating tax expenses	3,374	110	30,588	235
(Reversal) Estimated Loss from contingent liabilities	(37,910)	36,942	(37,910)	36,942
Selling and distribution expenses	1,370	6,211	4,123	16,422
Other general and administrative expenses	43,931	53,550	98,785	105,187
Bad debt expense	0	23,526	0	92,356
Total Operating Expenses	127,837	217,704	427,961	560,184
Loss from Operations	(92,840)	(250,663)	(339,067)	(576,989)
Other Income
Net interest (expense) income	(39,284)	1,328	(131,406)	3,978
Other (expense) income, net	(2,567)	(6,370)	(25,128)	(9,389)
Total Other Income, Net	(41,851)	(5,042)	(156,534)	(5,411)
Loss before Income Taxes	(134,691)	(255,705)	(495,601)	(582,400)
Income Tax Benefit (Expense)	(152)	0	(314)	0
Net loss	(134,843)	(255,705)	(495,915)	(582,400)
Net loss attributable to the noncontrolling interest	(20,955)	(61,720)	(89,280)	(114,889)
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$ (113,888)	$ (193,985)	$ (406,635)	$ (467,511)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	91,780,528	120,225,323	74,431,221